Skip to main content

Navigation group

Volumes

93 Publications

Volume 3 - 2024

Original Research

Published on 11 Sep 2024

REAL-LIFE EXPERIENCE WITH FIRST-LINE TREATMENT WITH DARATUMUMAB, BORTEZOMIB, MELPHALAN, AND PREDNISONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA INELIGIBLE FOR AUTOLOGOUS STEM-CELL TRANSPLANTATION

  • Amalia Domingo-González
  • Rafael Alonso Fernández
  • Ana Jiménez
  • Teresa De Soto Álvarez
  • Ana Lerma
  • Virginia Pradillo Fernández
  • Gonzalo Benzo Callejo
  • Jose Sánchez-Pina
  • Elena Landete
  • Alberto Velasco
Frontiers in Hematology
doi 10.3389/frhem.2024.1438233
  • 221 views

Study Protocol

Accepted on 20 Aug 2024

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)

  • Theo Leitner
  • Evgenii Shumilov
  • Christina Schwitlick
  • Raphael Koch
  • Franziska Hamm
  • Marion Högner
  • Florian Bassermann
  • Katja Weisel
  • Hermann Einsele
  • Leo Rasche
Frontiers in Hematology
doi 10.3389/frhem.2024.1436845